Skip to main content
. Author manuscript; available in PMC: 2013 Jun 1.
Published in final edited form as: Hematol Oncol Clin North Am. 2012 Jun;26(3):543–563. doi: 10.1016/j.hoc.2012.01.009

Table 2.

Phase III trials of bevacizumab in gynecologic cancers

Trial Site of Disease Drug Regimens Date
GOG 218 OvaCa CPB + PTX vs CBP +PTX + bev vs CBP + PTX + bev then maintenance bev Sept 2005 to Oct 2008
ICON-7 OvaCa CBP + PTX with and without bev then maintenance bev Opened Apr 2006
GOG 252 OvaCa IV vs IP platinum + PTX with IV bev then maintenance bev Opened Aug 2009
GOG 262 OvaCa Dose dense PTX with bev Awaiting NCI clearance
GOG 213 Platinum-sensitive recur OvaCa CBP + PTX with and without bev then maintenance bev Opened Dec 2007
OCEANS Platinum-sensitive recur OvaCa CBP + GCB with and without bev 2007–2011
AURELIA Platinum-resistant OvaCa PTX + TPT + LD with and without bev Opened Oct 2009
GCIG Stage II–IV or recur MucOvaCa CBP + PTX with and without bev then maintenance bev vs OX + CAP with and without bev then maintenance bev Opened Jan 2010
GOG 240 Stage IVB, recur CxCa CDDP + PTX with and without bev vs TPT/PTX with and without bev Opened Apr 2009

Abbreviations: CBP- carboplatin; PTX-paclitaxel; bev- bevacizumab; GCB- gemcitabine; TPT- topotecan; LD- liposomal doxorubicin; IV- intravenous; IP- intraperitoneal; CDDP- cisplatin; OX- oxiplatin; CAP- capecitabine; OvaCa - epithelial ovarian cancer, CxCa - cervical cancer, EndoCa -endometrial cancer, MucOvaCa – mucinous ovarian cancer, Recur - recurrent disease